Details

Autor(en) / Beteiligte

• Pan, Jin, PhD
• Li, Deguan, PhD
• Xu, Yanfeng, PhD
• Zhang, Junling, PhD
• Wang, Yueying, BS
• Chen, Mengyi, MS
• Lin, Shuai, MS
• Huang, Lan, BS
• Chung, Eun Joo, PhD
• Citrin, Deborah E., MD
• Wang, Yingying, PhD
• Hauer-Jensen, Martin, MD, PhD
• Zhou, Daohong, MD
• Meng, Aimin, MD

Titel

Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice

Ist Teil von

• International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.353-361

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose Ionizing radiation (IR)–induced pulmonary fibrosis (PF) is an irreversible and severe late effect of thoracic radiation therapy. The goal of this study was to determine whether clearance of senescent cells with ABT-263, a senolytic drug that can selectively kill senescent cells, can reverse PF. Methods and Materials C57BL/6J mice were exposed to a single dose of 17 Gy on the right side of the thorax. Sixteen weeks after IR, they were treated with 2 cycles of vehicle or ABT-263 (50 mg/kg per day for 5 days per cycle) by gavage. The effects of ABT-263 on IR-induced increases in senescent cells; elevation in the expression of selective inflammatory cytokines, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases; and the severity of the tissue injury and fibrosis in the irradiated lungs were evaluated 3 weeks after the last treatment, in comparison with the changes observed in the irradiated lungs before treatment or after vehicle treatment. Results At 16 weeks after exposure of C57BL/6 mice to a single dose of 17 Gy, thoracic irradiation resulted in persistent PF associated with a significant increase in senescent cells. Treatment of the irradiated mice with ABT-263 after persistent PF had developed reduced senescent cells and reversed the disease. Conclusions To our knowledge, this is the first study to demonstrate that PF can be reversed by a senolytic drug such as ABT-263 after it becomes a progressive disease. Therefore, ABT-263 has the potential to be developed as a new treatment for PF.